Brazil’s health regulator has clarified how its revised medical-cannabis framework will work, setting out a regulatory compromise that other countries should study carefully.
The model does not pretend that every authorised cannabis product has completed the full medicines-approval process. It also rejects the idea that patients should wait outside the legal system while conventional evidence catches up.
On 22 July, Brazil’s National Health Surveillance Agency, Anvisa, published a 65-page questions-and-answers document on RDC 1,015/2026. The resolution was issued in February and entered into force on 4 May. Companies with products already authorised were told to submit required adaptations by 1 August 2026.
The result is a controlled, transitional route for human medical use, with standards closer to pharmaceuticals than to a general consumer market.
A category built as a bridge
Brazil created a specific “cannabis product” category in 2019. Anvisa’s new guidance explains why it has retained that approach.
The agency says evidence confirming efficacy and safety remains limited for most studied conditions. Ending the category, however, could make lawful access harder for patients and reduce the chance that products eventually move into the fully registered medicines system.
The revised framework therefore keeps a time-limited Sanitary Authorisation. That authorisation can allow a product to be manufactured, imported and sold through pharmacies, but it is distinct from registration as a medicine. To remain on the market beyond that route, a company is expected to pursue the relevant medicines pathway.
This is not a semantic distinction. It tells patients what the regulator knows and what it has not yet concluded. Market access is being permitted under controls; full proof of benefit and risk has not been granted by association.
Stronger detail on quality
The July document is aimed mainly at companies, but several requirements affect patients directly.
Applicants must provide detailed information about starting materials, production stages and concentrations of CBD, THC and other cannabinoids where relevant. Quality-control methods must be validated, and stability evidence is required for finished-product batches.
Manufacturers and importers need the relevant Anvisa operating and special authorisations. The finished-product manufacturer must hold a valid good-manufacturing-practice certificate for the dosage form concerned.
The framework distinguishes highly purified CBD from plant extracts. It also makes clear that an imported product is assessed against Brazilian requirements regardless of how it is categorised in its country of origin.
These provisions are not glamorous, but they are the substance of regulation. Consistent composition, contamination controls and stability over time determine whether a clinician and patient are dealing with the same medicine from one batch to the next.
What the route excludes
RDC 1,015/2026 concerns cannabis products for human medicinal purposes. Anvisa’s guidance says it does not cover cannabis foods, cosmetics, smoking products or medical devices.
The product category is also not identical to the exceptional route that allows an individual to import cannabis-derived products for personal use under a separate resolution. Commercial authorisation and patient-by-patient import are different pathways with different responsibilities.
That separation is useful. “Medical cannabis access” is often treated as a single policy switch when it is really a set of questions about who may prescribe, which products may be supplied, how they are made, who pays and what evidence is required.
What Brazil is trying to balance
Anvisa describes the task plainly: preserve access while strengthening rational use and risk control.
That balance is difficult because the two sides move at different speeds. Patients with serious symptoms make decisions now. Robust comparative trials, manufacturing validation and full medicines registration take years.
A temporary authorisation can bridge that gap, but only if temporary does not become permanent by default. Companies need a credible incentive and a realistic route to generate evidence, not an indefinite lower bar that rewards staying outside full registration.
The updated framework tries to apply pressure in both directions. It maintains access, gives authorisations a defined life and applies medicine-like quality requirements. Whether it succeeds will depend on enforcement, affordability, the quality of evidence produced and how many products actually progress.
Lessons for the United Kingdom
The UK and Brazil have different health systems and legal structures, so direct transplantation would be simplistic. The comparison is still useful.
Britain rescheduled cannabis-based products for medicinal use in 2018, enabling specialist prescribing. Access then developed mainly through private clinics, while routine NHS prescribing remained rare. The legal door opened, but the evidence, commissioning and product-approval pathways did not move together.
Brazil’s language is more explicit about the middle category. Access under Sanitary Authorisation is neither an illicit workaround nor the same as full medicines registration. That clarity may help patients understand the status of a product and give regulators a defined mechanism for demanding better evidence.
The UK’s forthcoming ACMD review has been asked to consider whether private availability has weakened incentives to conduct trials for safe, effective and cost-effective NHS products. Brazil’s transition model raises the same underlying question: how do you permit access without allowing provisional evidence to become the final standard?
There is no automatic answer in a rulebook. Regulators can require a pathway, but manufacturers need viable study designs, researchers need access to standardised products and health systems need a route for adopting successful results.
What to watch next
The immediate test is compliance. Existing authorisation holders face the 1 August deadline for submitting adaptations required by the new resolution.
Beyond that, four measures will show whether the reform is working: the number of products that meet the new quality standards; the time Anvisa takes to assess applications; whether patient prices and continuity of supply improve or worsen; and how many products progress to full medicine registration.
Patient safety reporting also matters. A framework that expands access needs reliable pharmacovigilance and public information about adverse events, composition and authorisation status.
The editorial view
Brazil’s approach is more honest than either prohibition dressed as caution or commercial access dressed as proof.
It recognises unmet need, keeps a regulated supply route open and states that the evidence is still incomplete. Its success should not be measured only by the number of products on pharmacy shelves. It should be measured by whether those products become more consistent, more affordable and better supported by evidence.
The principle worth borrowing is simple: provisional access should be a bridge to stronger knowledge, not a place for the system to stop.
Key takeaways
- Anvisa’s revised RDC 1,015/2026 framework took effect on 4 May 2026.
- The July guidance explains a transitional Sanitary Authorisation for manufacturing, importing and selling medical cannabis products.
- The category is distinct from full registration as a medicine.
- Applicants face detailed quality, composition, stability and good-manufacturing-practice requirements.
- The framework covers human medicinal products, not foods, cosmetics or smoking products.
- Its long-term test is whether access leads to better evidence and full product registration.
